on Nyxoah SA. (isin : BE0974358906)
Nyxoah Receives FDA Approval and Reports Q2 2025 Results
Nyxoah SA, a medical technology company, has secured FDA approval for its Genio® system, commencing its commercial launch in the U.S. This marks a significant step for the company, emphasizing their innovative approach to treating Obstructive Sleep Apnea (OSA) through neuromodulation. The Genio system stands out as the first bilateral hypoglossal neurostimulation therapy in the U.S., highlighting its unique design and efficacy.
Financially, Nyxoah reported a revenue of €1.3 million for Q2 2025, a rise from €0.8 million in 2024, reflecting a 74% growth. Despite this, the company recorded an operating loss of €19.9 million, influenced by increased expenses in research, development, and commercial activities. Nyxoah's cash reserves saw a decrease to €43.0 million by June 30, 2025.
The company's recent strides emphasize its commitment to expanding its presence and solutions within the healthcare sector.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Nyxoah SA. news